GSK’s Hibsago FDA Approval: Big Breakthrough, Big Partnership Constraints
GSK’s FDA nod for Hibsago shows how a breakthrough can stall when partnership limits and lackluster leadership curb upside—learn why investors stay wary.
3 minutes to read
GSK PLC
GSK Shares Rise 0.73% on Oct 21, 2026: 52‑Week High, FDA Breakthrough Approvals & Market Snapshot
GSK stock rises 0.73% on Oct 21, 2026, with FDA approvals for Hibsago and Jemperli highlighting its oncology and viral‑disease focus.
3 minutes to read